Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Holdings Boosted by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,683 shares of the biopharmaceutical company’s stock after purchasing an additional 21 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Alexion Pharmaceuticals were worth $2,030,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Guardian Life Insurance Co. of America boosted its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 6 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at about $111,000. Huntington National Bank lifted its position in shares of Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares in the last quarter. Penserra Capital Management LLC lifted its position in shares of Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at about $160,000. 94.26% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded up 1.36% during midday trading on Friday, hitting $146.57. The stock had a trading volume of 1,166,069 shares. The stock has a market cap of $32.71 billion, a P/E ratio of 63.56 and a beta of 1.40. The stock has a 50-day moving average price of $138.46 and a 200-day moving average price of $124.64. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same period in the prior year, the firm posted $1.13 EPS. The business’s revenue for the quarter was up 21.1% on a year-over-year basis. Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current year.

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $161.00 price objective on the stock. Deutsche Bank AG reaffirmed a “buy” rating and set a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. Leerink Swann reissued an “outperform” rating and set a $182.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday. They noted that the move was a valuation call. SunTrust Banks, Inc. reissued a “buy” rating and set a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday. Finally, BMO Capital Markets reissued an “outperform” rating and set a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have given a strong buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average target price of $157.13.

COPYRIGHT VIOLATION WARNING: This article was posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/alexion-pharmaceuticals-inc-alxn-shares-bought-by-commonwealth-of-pennsylvania-public-school-empls-retrmt-sys/1603129.html.

In other news, Director Ann M. Veneman sold 835 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the transaction, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,070 shares of company stock valued at $2,416,869. 4.35% of the stock is currently owned by corporate insiders.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.